Absolute SPECT/CT quantification of cerebral uptake of ^99mTc-HMPAO for patients with neurocognitive disorders

Summary

It was reported from planar imaging studies that the cerebral uptake of injected ^99mTc-HMPAO activity is about 4–7% in humans. Recent work has shown that modern SPECT/ CT devices are able to quantify the tissue concentration of radioactivity in vivo in absolute units (Bq/ml), while avoiding the limitations of planar techniques. The aims of this study were (a) to determine the cerebral uptake of ^99mTc-HMPAO in absolute units in SPECT/CT, (b) to investigate potential differences in absolute tracer uptake for patients suspected of dementia. Patients, methods: We performed ^99mTc-HMPAO SPECT/CT in 65 patients with suspected dementia. ^99mTc-HMPAO uptake was determined using a previously published quantitative SPECT/CT protocol. The absolute HMPAO uptake and the results of a regionalized analysis were compared for MMSE and NINCDS-ADRDA based patient groups. Results: The mean absolute uptake of ^99mTc-HMPAO for our patient population was 4.3 ± 0.8% of the injected dose. The uptake, as well as the regionalized analysis yielded significantly different results for low ( 23) and high (>23) MMSE groups and also for some of the NINCDS-ADRDA groups. Conclusion: Our results show that the absolute cerebral uptake of ^99mTc-HMPAO is in the range of previously reported results, obtained by planar techniques. Absolute uptake is significantly different between the patient groups.

Zusammenfassung

Der Gesamtuptake von ^99mTc-HMPAO im menschlichen Gehirn wurde in früheren Studien mithilfe planarer Bildgebung auf ca. 4–7% der injizierten Dosis bestimmt. Kürzlich wurde gezeigt, dass ebenso mit modernen SPECT/CT-Geräten die In-vivo-Aktivitätskonzentration im Gewebe in absoluten Einheiten (Bq/ml) quantifiziert werden kann, bei gleichzeitiger Vermeidung der Limitationen der planaren Bildgebung. Die Ziele dieser Studie waren (a) den absoluten Uptake von ^99mTc-HMPAO mithilfe der SPECT/CT zu bestimmen, sowie (b) mögliche Unterschiede des absoluten Uptakes verschiedener Gruppen von Demenzpatienten zu ermitteln. Patienten, Methoden: In 65 Patienten mit Verdacht auf Demenzerkrankung wurden ^99mTc-HMPAO-SPECT/CT durchgeführt. Der absolute ^99mTc-HMPAO-Uptake wurde auf Basis einer bereits veröffentlichten Methode bestimmt. Darüber hinaus wurden gruppenspezifische HMPAO-Uptakes ermittelt und auf Unterschiede geprüft. Die Gruppeneinteilung erfolgte anhand von MMSE- und NINCDS-ADRDA-Kriterien. Die Ergebnisse wurden denen der Standardmethode, des regionalisierten Vergleichs mit einem Normkollektiv, gegenübergestellt. Ergebnisse: Der mittlere absolute Uptake von ^99mTc-HMPAO war 4,3 ± 0,8% der injizierten Dosis. Sowohl die absolute Quantifizierung, als auch der regionalisierte Vergleich mit dem Normkollektiv führte zu signifikant unterschiedlichen Ergebnissen für Gruppen mit niedrigen ( 23) bzw. hohen (>23) MMSE Werten und ebenso für NINCDS-ADRDA basierte Gruppen. Schlussfolgerung: Unsere Ergebnisse deuten darauf hin, dass der Gesamtuptake von ^99mTc-HMPAO im Gehirn im bisherigen, durch planare Bildgebung bestimmten Bereich ist. Es gibt zwischen den betrachteten Patientengruppen signifikante Unterschiede im Uptake.

Keywords

Absolute quantification - SPECT/CT - HMPAO - brain perfusion

Schlüsselwörter

Absolute Quantifizierung - SPECT/CT - HMPAO - Gehirnperfusion

• References

• 1 Apostolova I, Wunder A, Dirnagl U. et al. Brain perfusion SPECT in the mouse: normal pattern according to gender and age. Neuroimage 2012; 63: 1807-1817.
• 2 Bailey DL, Willowson KP. Quantitative SPECT/ CT: SPECT joins PET as a quantitative imaging modality. Eur J Nucl Med Mol Imaging 2014; 41: 17-25.
• 3 Barnden LR, Behin-Ain S, Kwiatek R. et al. Age related preservation and loss in optimized brain SPECT. Nucl Med Commun 2005; 26: 497-503.
• 4 Blacker D, Albert MS, Bassett SS. et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer’s disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 1994; 51: 1198-1204.
• 5 Bok BD, Scheffel U, Goldfarb H. et al Comparison of ^99mTc complexes (NEP-DADT, ME-NEP-DADT and HMPAO) with ¹²³IAMP for brain SPECT imaging in dogs. Nucl Med Commun 1987; 8: 631-641.
• 6 Borroni B, Anchisi D, Paghera B. et al. Combined ^99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging 2006; 27: 24-31.
• 7 Brookmeyer R, Johnson E, Ziegler-Graham K. et al. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 2007; 3: 186-191.
• 8 Cachovan M, Vija AH, Hornegger J. et al. Quantitative bone SPECT with a novel multimodal reconstruction. J Nucl Med 2013; 54: 338.
• 9 Cachovan M, Vija A, Hornegger J. et al. Quantification of ^99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res 2013; 3: 45.
• 10 Chen YJ, Deutsch G, Satya R. et al. A semi-quantitative method for correlating brain disease groups with normal controls using SPECT: Alzheimer’s disease versus vascular dementia. Comput Med Imaging Graph 2013; 37: 40-47.
• 11 Costa DC, Ell PJ, Cullum ID. et al. The in vivo distribution of ^99mTc-HM-PAO in normal man. Nucl Med Commun 1986; 7: 647-658.
• 12 Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004; 12: 554-570.
• 13 Dubois B, Feldman HH, Jacova C. et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
• 14 Duran FL, Zampieri FG, Bottino CC. et al. Voxelbased investigations of regional cerebral blood flow abnormalities in Alzheimer’s disease using a single-detector SPECT system. Clinics (Sao Paulo) 2007; 62: 377-384.
• 15 Folstein MF, Folstein SE, McHugh PR. „Minimental state“. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
• 16 Hogervorst E, Bandelow S, Combrinck M. et al. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer’s disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach. Dement Geriatr Cogn Disord 2003; 16: 170-180.
• 17 Hogh P, Teller AS, Hasselbalch S. et al Visual rating and ROI-based parametric analysis of rCBF SPECT in patients with mild or questionable dementia: a comparative study. Dement Geriatr Cogn Disord 2007; 24: 429-433.
• 18 Huang C, Eidelberg D, Habeck C. et al. Imaging markers of mild cognitive impairment: multivariate analysis of CBF SPECT. Neurobiol Aging 2007; 28: 1062-1069.
• 19 Inoue K, Nakagawa M, Goto R. et al. Regional differences between ^99mTc-ECD and ^99mTc-HMPAO SPET in perfusion changes with age and gender in healthy adults. Eur J Nucl Med Mol Imaging 2003; 30: 1489-1497.
• 20 Ishii K, Sasaki M, Sakamoto S. et al. Tc-99m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-D-glucose PET in Alzheimer’s disease. Comparison of perfusion and metabolic patterns. Clin Nucl Med 1999; 24: 572-575.
• 21 Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 1998; 10: 271-302.
• 22 Kapucu OL, Nobili F, Varrone A. et al. EANM procedure guideline for brain perfusion SPECT using ^99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging 2009; 36: 2093-2102.
• 23 Lampl Y, Sadeh M, Laker O. et al. Correlation of neuropsychological evaluation and SPECT imaging in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2003; 18: 288-291.
• 24 Lucignani G, Rossetti C, Ferrario P. et al. In vivo metabolism and kinetics of ^99mTc-HMPAO. Eur J Nucl Med 1990; 16: 249-255.
• 25 Matsuda H, Mizumura S, Nagao T. et al. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol 2007; 28: 731-736.
• 26 McKhann G, Drachman D, Folstein M. et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-944.
• 27 Minoshima S, Frey KA, Foster NL. et al. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995; 19: 541-547.
• 28 Muller H, Moller HJ, Stippel A. et al. SPECT patterns in probable Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 1999; 249: 190-196.
• 29 Neirinckx RD, Burke JF, Harrison RC. et al. The retention mechanism of technetium-99m-HM-PAO: Intracellular reaction with glutathione. J Cereb Blood Flow Metab 1988; 8: S4-S12.
• 30 Neirinckx RD, Canning LR, Piper IM. et al. Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 1987; 28: 191-202.
• 31 Nobili F, Koulibaly PM, Rodriguez G. et al. ^99mTc-HMPAO and ^99mTc-ECD brain uptake correlates of verbal memory in Alzheimer’s disease. Q J Nucl Med Mol Imaging 2007; 51: 357-363.
• 32 Ones T, Midi I, Dede F. et al. Initial mini-mental state and cerebral perfusion in Alzheimer’s disease. Clin Neuroradiol 2012; 22: 219-226.
• 33 Pagani M, Salmaso D, Jonsson C. et al. Regional cerebral blood flow as assessed by principal component analysis and ^99mTc-HMPAO SPET in healthy subjects at rest: normal distribution and effect of age and gender. Eur J Nucl Med Mol Imaging 2002; 29: 67-75.
• 34 Podreka I, Suess E, Goldenberg G. et al. Initial experience with technetium-99m HM-PAO brain SPECT. J Nucl Med 1987; 28: 1657-1666.
• 35 Sanders JC, Kuwert T, Hornegger J. et al. Quantitative SPECT/CT imaging of ¹⁷⁷Lu with in vivo validation in patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol 2015; 17: 585-593.
• 36 Scheltens P, Korf ES. Contribution of neuroimaging in the diagnosis of Alzheimer’s disease and other dementias. Curr Opin Neurol 2000; 13: 391-396.
• 37 Sharp PF, Smith FW, Gemmell HG. et al. Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med 1986; 27: 171-177.
• 38 Shin W, Horowitz S, Ragin A. et al. Quantitative cerebral perfusion using dynamic susceptibility contrast MRI: Evaluation of reproducibility and age- and gender-dependence with fully automatic image postprocessing algorithm. Magn Reson Med 2007; 58: 1232-1241.
• 39 Sousa RM, Ferri CP, Acosta D. et al. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet 2009; 374: 1821-1830.
• 40 Staffen W, Bergmann J, Schonauer U. et al. Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer’s type: a semiquantitative and automated evaluation. Eur J Nucl Med Mol Imaging 2009; 36: 801-810.
• 41 Vija AHH, Engdahl E.G., John C. Analysis of a SPECT OSEM reconstruction method with 3D beam modeling and optional attenuation correction: phantom studies. Nuclear Science Symposium Conference Record 2003 IEEE. 19–25 Oct 2003 2662, 2666
• 42 Wang CL, Cohan RH, Ellis JH. et al. Frequency, management, and outcome of extravasation of nonionic iodinated contrast medium in 69 657 intravenous injections. Radiology 2007; 243: 80-87.
• 43 Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement 2010; 6: 98-103.
• 44 Yoon HJ, Park KW, Jeong YJ. et al. Correlation between neuropsychological tests and hypoperfusion in MCI patients: anatomical labeling using xjView and Talairach Daemon software. Ann Nucl Med 2012; 26: 656-664.
• 45 Zeintl J, Vija AH, Yahil A. et al. Quantitative accuracy of clinical ^99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. J Nucl Med 2010; 51: 921-928.